Annual report pursuant to Section 13 and 15(d)

NOTES PAYABLE (Details 1)

v3.21.1
NOTES PAYABLE (Details 1)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2020
USD ($)
Equity_Instrument
$ / shares
Dec. 31, 2019
USD ($)
Equity_Instrument
Feb. 28, 2020
Debt Instrument [Line Items]      
Interest rate     10.00%
Conversion Price | $ / shares $ 10.00    
Principal Outstanding $ 15,294 $ 17,142  
Discount Amount 1,720 3,190  
Carrying Amount $ 13,574 $ 13,952  
Shares Underlying Notes | Equity_Instrument 320,353 1,444,291  
2019 Convertible Debentures [Member]      
Debt Instrument [Line Items]      
Interest rate 10.00%    
Term of Notes 18 months    
Principal Outstanding $ 7,200 $ 10,200  
Discount Amount 1,720 3,185  
Carrying Amount $ 5,480 $ 7,015  
Shares Underlying Notes | Equity_Instrument 3,630 [1] 1,080,415  
2019 Convertible Debentures [Member] | Minimum [Member]      
Debt Instrument [Line Items]      
Conversion Price | $ / shares $ 2.00    
2019 Convertible Debentures [Member] | Maximum [Member]      
Debt Instrument [Line Items]      
Conversion Price | $ / shares $ 9.52    
Convertible Debentures [Member]      
Debt Instrument [Line Items]      
Principal Outstanding $ 7,200 $ 10,200  
Discount Amount 1,720 3,185  
Carrying Amount $ 5,480 $ 7,015  
Shares Underlying Notes | Equity_Instrument 3,630 1,080,415  
Principal Outstanding, Current $ 7,200 $ 10,200  
Discount Amount Current 1,720 3,185  
Convertible Debentures, Current $ 5,480 $ 7,015  
[1] The notes are convertible into Emmaus Life Sciences, Inc. shares.